NCT00002353View on ClinicalTrials.gov

A Phase I Safety and Immunogenicity Trial of UBI HIV Lipopeptide Immunotherapeutic P3C541b in HIV-1 Seropositive Human Subjects

PHASE1CompletedINTERVENTIONAL
Timeline

Start Date

Not specified

Conditions
HIV Infections
Interventions
BIOLOGICAL

P3C541b Lipopeptide

Trial Locations (1)

02215

Beth Israel Hosp, Boston

All Listed Sponsors
lead

United Biomedical

INDUSTRY